Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies

Area of Science:

• Neurology
• Genetics
• Molecular Biology

Background:

• Amyotrophic lateral sclerosis (ALS) is the most common neuromuscular degenerative disorder.
• Median survival time for ALS patients is 3-5 years.
• ALS pathogenesis involves multifactorial mechanisms, including genetic and molecular pathway interactions.

Purpose of the Study:

• To explore the pathophysiological mechanisms of ALS.
• To identify genetic and molecular factors contributing to ALS.
• To discuss novel therapeutic strategies for ALS.

Main Methods:

• Review of genetic associations with ALS, including 16 identified genes and loci.
• Analysis of molecular pathways implicated in ALS, such as RNA metabolism and excitotoxicity.
• Examination of emerging therapeutic approaches.

Main Results:

• Mutations in DNA/RNA-regulating genes, notably c9orf72, are linked to ALS.
• Dysregulation of RNA metabolism is suggested as a key factor in ALS pathogenesis.
• Common pathogenic pathways, including glutamate excitotoxicity, are identified in both sporadic and familial ALS.

Conclusions:

• Understanding ALS pathophysiology reveals complex genetic and molecular underpinnings.
• Novel therapeutic avenues, including stem cell and gene-based therapies, are emerging.
• These advancements offer hope for effective ALS treatment.